Long-term survival outcomes of salvage [ 225 Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.
Sanjana BallalMadhav P YadavSwayamjeet SatapathyShobhana RajuMadhavi TripathiNishikant A DamleRanjit K SahooChandrasekhar BalPublished in: European journal of nuclear medicine and molecular imaging (2023)
Ac]Ac-PSMA-617 targeted alpha therapy, was found to be well-tolerated with acceptable adverse events and effective in the treatment of patients with end-stage mCRPC.